Do Engineered Nanomaterials Affect Immune Responses by Interacting With Gut Microbiota?

Identification of CREB5 as a prognostic and immunotherapeutic biomarker in glioma through multi-omics pan-cancer analysis

BACKGROUND

The functional relevance of cyclic adenosine monophosphate (cAMP)-response element-binding protein 5 (CREB5) in cancers remains elusive, despite its significance as a member of the CREB family. The current research aims to explore the role of CREB5 in multiple cancers.

METHODS

Pan-cancer analysis was performed to explore the expression patterns, prognostic value, mutational landscape as well as single-cell omic, immunologic, and drug sensitivity profiles of CREB5. Furthermore, we incorporated five distinct machine learning algorithms and determined that the least absolute shrinkage and selection operator-COX (LASSO-COX) algorithm, which exhibited the highest C index, was the optimal selection. Subsequently, we constructed a prognostic model centered around CREB5-associated genes. To elucidate the biological function of CREB5 in glioma cells, several assays including cell counting kit-8 (CCK-8), wound healing, transwell, flow cytometric were performed.

RESULTS

CREB5 was overexpressed in pan-cancer and was linked to unfavorable prognosis, particularly in glioma. Furthermore, genetic alterations were determined in various types of cancer, and modifications in the CREB5 gene were linked to the prognosis. The single-cell omics and enrichment analyses showed that CREB5 was predominantly expressed in malignant glioma cells and was critically involved in the regulation of various oncogenic processes. Elevated levels of CREB5 were strongly linked with the infiltration of cancer-associated fibroblasts and the Th1 subset of CD4+ T cells. The validated CREB5-associated prognostic model reliably predicted the prognosis and drug response of glioma patients. The in vitro experiments showed that CREB5 promoted glioma cell proliferation, invasion, migration, and gap phase 2/mitotic (G2/M) phase arrest and recruited M2 macrophages into glioma cells.

CONCLUSION

CREB5 has the potential to act as an oncogene and a biological marker in multiple cancers, particularly glioma.

Engineered Nanomaterials for Immunomodulation: A Review

The immune system usually provides a defense against invading pathogenic microorganisms and any other particulate contaminants. Nonetheless, it has been recently reported that nanomaterials can evade the immune system and modulate immunological responses due to their unique physicochemical characteristics. Consequently, nanomaterial-based activation of immune components, i.e., neutrophils, macrophages, and other effector cells, may induce inflammation and alter the immune response. Here, it is essential to distinguish the acute and chronic modulations triggered by nanomaterials to determine the possible risks to human health. Nanomaterials size, shape, composition, surface charge, and deformability are factors controlling their uptake by immune cells and the resulting immune responses. The exterior corona of molecules adsorbed over nanomaterials surfaces also influences their immunological effects. Here, we review current nanoengineering trends for targeted immunomodulation with an emphasis on the design, safety, and potential toxicity of nanomaterials. First, we describe the characteristics of engineered nanomaterials that trigger immune responses. Then, the biocompatibility and immunotoxicity of nanoengineered particles are debated, because these factors influence applications. Finally, future nanomaterial developments in terms of surface modifications, synergistic approaches, and biomimetics are discussed.

Toxicity of carbon nanofibers in earthworms (Lumbricus terrestris) naturally infected with Monocystis sp

Although the ecotoxicity of carbon-based nanomaterials (CBNs) is known, the potential effect of carbon nanofibers (CNFs) on edaphic organisms has been insufficiently explored. Thus, we aimed at the ecotoxicity of CNFs (at 10 and 100 mg/kg) in Lumbricus terrestris earthworms naturally infected with Monocystis sp. After 28 days of exposure, treatments did not affect the survival rate. However, we observed a significant loss of body biomass, and Monocystis sp. infection in seminal vesicles was potentiated by exposure to CNFs. Earthworms exposed to CNFs showed a redox imbalance in the seminal vesicle, muscle, and intestine and an alteration in nitric oxide production in these organs. In muscles, we also noticed a significant reduction in AChE activity in earthworms exposed to CNFs. The histopathological analyses revealed the treatments' significant effect on the structures of the different evaluated tissues. Although we did not notice a concentration-response for several of the biomarkers, when taken together and after the application of Integrated Biomarker Response (IBR) and principal component analysis (PCA), we noticed that the response of earthworms to CNFs at 100 mg/kg showed a more significant deviation from the unexposed group. This was mainly determined by inhibiting antioxidant activity in the seminal vesicle, biochemical biomarkers assessed in muscle and intestine, and histomorphometric muscle biomarkers from earthworms exposed to CNFs at 100 mg/kg. Thus, we demonstrate that CNFs increase the parasite load of Monocystis sp. of adult L. terrestris earthworms and induce biochemical and histopathological changes, especially at 100 mg/kg. Our results point to the additional impact these nanomaterials can have on the health of earthworms, signaling the need for greater attention to their disposal and ecotoxicological effects on soil organisms.

Changes of physico-chemical properties of nano-biomaterials by digestion fluids affect the physiological properties of epithelial intestinal cells and barrier models

Background

The widespread use of nano-biomaterials (NBMs) has increased the chance of human exposure. Although ingestion is one of the major routes of exposure to NBMs, it is not thoroughly studied to date. NBMs are expected to be dramatically modified following the transit into the oral-gastric-intestinal (OGI) tract. How these transformations affect their interaction with intestinal cells is still poorly understood. NBMs of different chemical nature—lipid-surfactant nanoparticles (LSNPs), carbon nanoparticles (CNPs), surface modified Fe₃O₄ nanoparticles (FNPs) and hydroxyapatite nanoparticles (HNPs)—were treated in a simulated human digestive system (SHDS) and then characterised. The biological effects of SHDS-treated and untreated NBMs were evaluated on primary (HCoEpiC) and immortalised (Caco-2, HCT116) epithelial intestinal cells and on an intestinal barrier model.

Results

The application of the in vitro SDHS modified the biocompatibility of NBMs on gastrointestinal cells. The differences between SHDS-treated and untreated NBMs could be attributed to the irreversible modification of the NBMs in the SHDS. Aggregation was detected for all NBMs regardless of their chemical nature, while pH- or enzyme-mediated partial degradation was detected for hydroxyapatite or polymer-coated iron oxide nanoparticles and lipid nanoparticles, respectively. The formation of a bio-corona, which contains proteases, was also demonstrated on all the analysed NBMs. In viability assays, undifferentiated primary cells were more sensitive than immortalised cells to digested NBMs, but neither pristine nor treated NBMs affected the intestinal barrier viability and permeability. SHDS-treated NBMs up-regulated the tight junction genes (claudin 3 and 5, occludin, zonula occludens 1) in intestinal barrier, with different patterns between each NBM, and increase the expression of both pro- and anti-inflammatory cytokines (IL-1β, TNF-α, IL-22, IL-10). Notably, none of these NBMs showed any significant genotoxic effect.

Conclusions

Overall, the results add a piece of evidence on the importance of applying validated in vitro SHDS models for the assessment of NBM intestinal toxicity/biocompatibility. We propose the association of chemical and microscopic characterization, SHDS and in vitro tests on both immortalised and primary cells as a robust screening pipeline useful to monitor the changes in the physico-chemical properties of ingested NBMs and their effects on intestinal cells.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12989-022-00491-w.

Gut microbiome interactions with graphene based nanomaterials: Challenges and opportunities

Rapid growth of nanotechnology has accelerated immense possibility of engineered nanomaterials (ENMs) exposure by human and living organisms. In this context, wide range applications of graphene based nanomaterials (GBNMs) may inevitably cause their release into the environment. Consequently, potential risks to the ecological system and human health is consistently increasing due to the probable ingestion of GBNMs by mean of contaminated water or food sources. Further, gut microbiome is known to play a profound impact on the health status of human being and has been recognized as the most exciting advancement in the biomedical science. Recent studies has shown vital role of ENMs to alter gut microbiome and thereby changed pathological status of organisms. Therefore, in this review results of numerous studies dedicated to explore the impact of GBNMs on gut microbiome and thereby various pathological status have been summarized. Dietary exposure of different types of GBNMs [e.g. graphene, graphene oxide (GO), partially reduced graphene oxide (PRGO), graphene quantum dots (GQDs)] have been evaluated on the gut microbiome through numerous in vitro and in vivo models. Moreover, emphasis has been made to evaluate different physiological responses with the short/long-term exposure of GBNMs, particularly in gastrointestinal tract (GIT) and its correlation with gut microbiome and the health status. It is reviewed that exposure of GBNMs can exert significant impact which alter the composition, diversity and function of gut microbiome. This may further appear in terms of enteric disorder along with numerous pathological changes e.g. IEC (intestinal epithelial cells) colitis, lysosomal dysfunction, inflammation, shortened colon, resorbed embryo, retardation in skeletal development, low weight of fetus, early or late dead of fetus and IBD (inflammatory bowel disease) like symptoms. Finally, potential health risks due to the exposure of GBNMs have been discussed with future perspective.

In Vitro and In Vivo Models to Assess the Immune-Related Effects of Nanomaterials

The immunological safety of drugs, nanomaterials and contaminants is a central point in the regulatory evaluation and safety monitoring of working and public places and of the environment. In fact, anomalies in immune responses may cause diseases and hamper the physical and functional integrity of living organisms, from plants to human beings. In the case of nanomaterials, many experimental models are used for assessing their immunosafety, some of which have been adopted by regulatory bodies. All of them, however, suffer from shortcomings and approximations, and may be inaccurate in representing real-life responses, thereby leading to incomplete, incorrect or even misleading predictions. Here, we review the advantages and disadvantages of current nanoimmunosafety models, comparing in vivo vs. in vitro models and examining the use of animal vs. human cells, primary vs. transformed cells, complex multicellular and 3D models, organoids and organs-on-chip, in view of implementing a reliable and personalized nanoimmunosafety testing. The general conclusion is that the choice of testing models is key for obtaining reliable predictive information, and therefore special attention should be devoted to selecting the most relevant and realistic suite of models in order to generate relevant information that can allow for safer-by-design nanotechnological developments.